Skip to content

13F-HR filed by ACUTA CAPITAL PARTNERS, LLC

ACUTA CAPITAL PARTNERS, LLC filed this 13F-HR for the quarter ended 2021-06-30, filed 2021-08-16, with 38 holding rows worth $250,241,000.

Accession
0001104659-21-105963
Filed
2021-08-16
Accepted by EDGAR
acceptance time not in the bulk data set
Ingested
Source
SEC quarterly data set

Original filing

13F report for Q2 2021

A holdings report, 38 entries on the cover page, a total value of $250,241,000 stated on the cover page (in dollars after the unit check, H1), rows summing to $250,241,000 with VALUE read as thousands by filing date, 13F file number 028-16527. The quarter's positions are built on this report. The resolved quarter.

The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).

Issuer as filedCUSIPClassAmountValueValue read asType
VISTAGEN THERAPEUTICS INC92840H202COM11,728,033$36,943,000thousands by filing date
CELLDEX THERAPEUTICS INC NEW15117B202COM NEW987,406$33,019,000thousands by filing date
CELLDEX THERAPEUTICS INC NEW15117B202COM NEW500,000$16,720,000thousands by filing dateput
APELLIS PHARMACEUTICALS INC03753U106COM160,500$10,144,000thousands by filing date
ARROWHEAD PHARMACEUTICALS IN04280A100COM108,000$8,945,000thousands by filing date
BCLS ACQUISITION CORPG0904B105CMN843,122$8,878,000thousands by filing date
VERASTEM INC92337C104COM2,018,433$8,215,000thousands by filing date
IVERIC BIO INC46583P102COM1,250,000$7,888,000thousands by filing date
XENON PHARMACEUTICALS INC COM98420N105Stock417,409$7,772,000thousands by filing date
SEELOS THERAPEUTICS INC81577F109COM2,860,000$7,550,000thousands by filing date
KURA ONCOLOGY INC COM50127T109Stock353,398$7,368,000thousands by filing date
ESSA PHARMA INC29668H708COM NEW232,896$6,654,000thousands by filing date
CLEARSIDE BIOMEDICAL INC185063104COM1,316,268$6,410,000thousands by filing date
FULCRUM THERAPEUTICS INC359616109COMMON STOCK604,074$6,331,000thousands by filing date
VINCERX PHARMA INC92731L106COM NEW478,401$6,214,000thousands by filing date
CYTEIR THERAPEUTICS INC23284P103COMMON277,777$5,944,000thousands by filing date
JIYA ACQUISITION CORP47760M102CMN562,500$5,591,000thousands by filing date
ATHIRA PHARMA INC04746L104COM427,060$4,373,000thousands by filing date
ALIGOS THERAPEUTICS INC COM NEW01626L105Stock214,254$4,368,000thousands by filing date
SELECTA BIOSCIENCES INC816212104COM1,024,668$4,283,000thousands by filing date
CHIMERIX INC COM16934W106Stock509,164$4,073,000thousands by filing date
HEALTH SCIENCES ACQ CORP 2G4411D109ORD SHS392,500$4,004,000thousands by filing date
IOVANCE BIOTHERAPEUTICS INC462260100COM149,495$3,890,000thousands by filing date
AVADEL PHARMACEUTICALS, PLC05337M104COMMON STOCK-FO561,011$3,776,000thousands by filing date
SYNDAX PHARMACEUTICALS INC87164F105COM206,126$3,539,000thousands by filing date
EYEPOINT INC COM NEW30233G209Stock369,863$3,325,000thousands by filing date
GH RESEARCH PLC ORDINARY SHARESG3855L106Stock150,000$3,260,000thousands by filing date
ACLARIS THERAPEUTICS INC COM00461U105Stock175,000$3,073,000thousands by filing date
CATALYST BIOSCIENCES INC14888D208COM685,000$2,966,000thousands by filing date
SAGE THERAPEUTICS INC78667J108COM50,945$2,894,000thousands by filing date
RAIN ONCOLOGY INC75082Q105COM162,245$2,521,000thousands by filing date
CATABASIS PHARMACEUTICALS IN14875P206COM NEW1,173,674$2,476,000thousands by filing date
CATALYST PHARMACEUTICALS INC14888U101COM329,134$1,893,000thousands by filing date
AVIDITY BIOSCIENCES INC COM05370A108Stock60,000$1,483,000thousands by filing date
REATA PHARMACEUTICALS INC75615P103CL A10,000$1,415,000thousands by filing date
CYMABAY THERAPEUTICS INC23257D103COM301,904$1,316,000thousands by filing date
NOVAVAX INC670002401COM NEW2,315$491,000thousands by filing date
NUVATION BIO INC67080N119WARR90,832$236,000thousands by filing date

Amendment chain

FilingRoleFiledAcceptedIngested
13F-HR 0001104659-21-105963this filing2021-08-16acceptance time not in the bulk data set